A preclinical study shows that the anti-epileptic drug levetiracetam can prevent the formation of amyloid-beta 42 in neurons by modulating synaptic vesicle recycling. Analysis of patient records indicates a modest delay in cognitive decline among Alzheimer's patients taking the drug, suggesting potential for very early preventive use.
People with Down syndrome have a 90% to 95% lifetime risk of Alzheimer’s disease. Amyloid accumulation is almost inevitable by age 40, and baseline assessment is recommended by age 40 with annual follow-up.
Northwestern University researchers found that levetiracetam, an FDA-approved anti-seizure medication, prevents formation of toxic amyloid-beta 42 peptides in the brain, offering a potential strategy for early Alzheimer's prevention.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07778654 |
Vestibular Stimulation Versus Foot Intrinsic Muscle Exercises in Children With Down Syndrome |
NOT_YET_RECRUITING | NA |
| NCT07756944 |
Effects of Bubble Cushion Exercises on Postural Control in Children With Down Syndrome |
COMPLETED | NA |
| NCT07702201 |
MOTOR PROFICIENCY AND HEALTH-RELATED FITNESS IN DOWN SYNDROME |
COMPLETED | |
| NCT07653399 |
Neurodevelopmental Treatment for Balance and Mobility in Children With Down Syndrome |
COMPLETED | NA |
| NCT07631130 |
Home and Community Use of a Suspension Walker in Pre-Walking Infants With Down Syndrome |
NOT_YET_RECRUITING | NA |
| NCT07625579 |
Collaboration for Down Syndrome Progress (CDP) |
RECRUITING | |
| NCT07416201 |
Natural History of Dysregulation and Aging of the Immune System in People With Trisomy 21 With and Without Thymectomy |
RECRUITING | |
| NCT07296861 |
HomeGrown: A Family-based Lifestyle Intervention to Support Healthy Development of Young Children With Down Syndrome |
RECRUITING | NA |
| NCT07044804 |
Non-Invasive Brain Stimulation to Improve Language in Down Syndrome. |
RECRUITING | NA |
| NCT06951516 |
How Simplified Language Affects Comprehension and Learning in Young Children With Down Syndrome |
RECRUITING | NA |
